Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gynecologic 1CNS 1

Conditions

Neoplasms, Glandular and Epithelial 2Carcinoma 2Uterine Cervical Dysplasia 1Urogenital Neoplasms 1Ovarian Neoplasms 1Ovarian Diseases 1Neoplasms 1Neoplasm Metastasis 1Gonadal Disorders 1Genital Neoplasms, Female 1Genital Diseases, Female 1Female Urogenital Diseases and Pregnancy Complications 1Female Urogenital Diseases 1Endocrine System Diseases 1Endocrine Gland Neoplasms 1Adnexal Diseases 1

Interventions

Paclitaxel 28Carboplatin 28pembrolizumab 25Bevacizumab 14liposomal doxorubicin 12Cisplatin 11Gemcitabine 10Radiotherapy 8Drug Therapy 8Cyclophosphamide 8Blood Specimen Collection 8Topotecan 7Nivolumab 7olaparib 6Doxorubicin 6niraparib 5Therapeutics 5Dexamethasone 5pertuzumab 4pazopanib 4lenvatinib 4fludarabine 4cemiplimab 4atezolizumab 4Trastuzumab 4Surveys and Questionnaires 4Psychiatric Rehabilitation 4Polymerase Chain Reaction 4Fulvestrant 4Docetaxel 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Ocoxin × Gynecologic × Clear all
NCT03549273 2024-02-07

Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions

Catalysis SL

Phase 2 Unknown
62 enrolled
Gynecologic

Carcinoma, Uterine Cervical Dysplasia, Neoplasms, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon ⚡